Methods for preparing biocompatible polymer compounds and transdermal drug delivery systems containing polymer compounds

By preparing polydimethylsilylethylenedimethylsiloxane (PDDS) compounds, the problems of drug delivery efficiency and biocompatibility in existing transdermal drug delivery systems have been solved, achieving efficient drug delivery and therapeutic effects.

CN123125264APending Publication Date: 2026-11-17DASHAN PHARMACEUTICAL CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202580028262.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-15
Filing Date
2025-03-11
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing transdermal drug delivery systems have limitations in terms of drug delivery efficiency and biocompatibility, making it difficult to simultaneously load various drugs and effectively deliver them to the dermis.

Method used

Poly(dimethylsilylethylenedimethylsiloxane) (PDDS) compound represented by Formula 1 was used to prepare a polymer with a cyclic siloxane structure by ring-opening polymerization. The hydroxyl groups of chitosan and hyaluronic acid were then combined to form a highly biocompatible and controllable polymer compound.

Benefits of technology

It achieves high biocompatibility and high absorption rate, effectively delivering drugs to the epidermis, dermis and subcutaneous tissues, significantly improving drug penetration and absorption rate, and is suitable for treating diseases such as Alzheimer's disease, tumors and hair loss.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125264A_ABST
    Figure CN123125264A_ABST
Patent Text Reader

Abstract

This invention relates to novel polymer compounds and transdermal drug delivery systems comprising said polymer compounds. The polymer compounds according to embodiments of the invention exhibit high biocompatibility, can be loaded with various active substances, and can be used to increase the transdermal absorption of said active substances.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for preparing biocompatible polymer compounds and a transdermal drug delivery system comprising said polymer compounds. Background Technology

[0002] Transdermal drug delivery systems (TDDS) have attracted attention as a promising method of drug delivery, particularly for the treatment of skin diseases, through transdermal drug delivery. Because TDDS deliver drugs into the body without passing through the gastrointestinal tract, it can be administered without gastrointestinal side effects such as abdominal pain and heartburn, and allows for easy control of blood concentrations. Therefore, it can address the low bioavailability associated with oral administration and reduce side effects and toxicity. Furthermore, since administration is not affected by patient aversion or rejection of the drug, it is simple and practical for patients with violent tendencies or limited mobility.

[0003] Transdermal drug delivery materials technology can provide better persistence, sustained release and selectivity than traditional formulations, thereby maximizing therapeutic effects and minimizing side effects, while also providing cost-effectiveness and ease of use by achieving maximum drug efficacy with minimal drug dosage.

[0004] To date, transdermal drug delivery systems have evolved into various forms, including gels, liposomes, patches, and microneedles.

[0005] First, gel formulations do not require complex systems or platforms. The gel (typically a polymer) and the drug form a three-dimensional network that reduces molecular fluidity and encapsulates the drug. Because gel formulations deliver the drug into the skin via passive diffusion, the encapsulated drug must have a low molecular weight (less than about 600 Da), sufficient hydrophobicity, and must be effective at low doses.

[0006] Among various gelling agents, chitosan, a natural polymer containing a high proportion of glucosamine in its structure, is widely used in gel pharmaceutical formulations due to its non-toxicity and easy degradation. While chitosan offers the advantage of acquiring a positive charge under mildly acidic conditions, thereby depolarizing negatively charged cell membranes, lowering membrane potential, and promoting the absorption of active ingredients or drugs, it also has drawbacks. Specifically, the partial protonation of the amino groups in chitosan can lead to the degradation of encapsulated drugs in the presence of soluble proteases at physiological pH.

[0007] Due to their unique structure, including a polar head and a nonpolar tail, liposome formulations can encapsulate both hydrophilic and hydrophobic drugs. The lipid bilayer fuses with the stratum corneum and is absorbed into the skin. Smaller liposomes have a higher specific surface area and more contact points with the skin, which facilitates drug penetration.

[0008] Hyaluronic acid, an anionic polysaccharide composed of N-acetylglucosamine and glucuronic acid, is widely used in liposome particles due to its moisturizing properties and biocompatibility. Hyaluronic acid-based nanoliposomes exhibit high particle stability due to electrostatic, steric, and hydrophobic interactions with drugs and biomolecules, and excellent stratum corneum permeability due to the flexibility of their structure. However, increased hydration at the skin surface can promote drug retention in the highly hydrated epidermis, thereby limiting drug delivery to the dermis.

[0009] Patch formulations are adhesive patches containing drugs that adhere to the skin to deliver a specific dose of drug through the skin into the bloodstream or to distribute the drug within the skin. Patches comprise an inert polymer that provides support and a platform for drug release, a drug dissolved or dispersed in a matrix, and a flexible backing layer that provides good adhesion to the drug reservoir.

[0010] Poly(dimethylsiloxane) (PDMS) is most widely used in transdermal patch formulations due to its inert and non-toxic properties, which include a reservoir, a matrix, and a drug-eluting adhesive layer. However, the strong hydrophobicity of PDMS can lead to strong binding with the encapsulated drug, thereby limiting drug release.

[0011] Microneedle drug delivery uses micron-sized needles to penetrate the stratum corneum to depths of 50 μm to 900 μm. The small needle size causes less pain and allows for precise drug delivery to the target depth. The polymers used to manufacture microneedles must possess high water solubility, biocompatibility, and mechanical strength for insertion into the skin.

[0012] Poly(lactide-co-glycolic acid) (PLGA) is widely used as a microneedle material due to its mechanical strength, high loading efficiency, biodegradability, and biocompatibility. PLGA has water-soluble and non-toxic degradation products, and its degradation rate can be controlled according to the chain length (molecular weight) and the lactide / glycolic acid ratio. However, PLGA-based microneedles must remain inserted into the skin for several days to release the loaded drug.

[0013] As mentioned above, conventional transdermal formulations have limited drug reach to the dermis and can only load a limited number of drugs. Therefore, there is a need for new formulations that can load a variety of drugs and improve drug delivery and biocompatibility to overcome the limitations of low drug penetration and the inability to load only drugs suitable for specific environments.

[0014] Despite the existence of various diseases, drug delivery systems suitable for actual patients remain underdeveloped. Therefore, there is a need for novel drug delivery systems that simultaneously consider both patient and drug characteristics. The inventors have achieved this invention by developing a biocompatible, silicone-based transdermal drug delivery system suitable for various diseases and capable of effectively increasing drug delivery.

[0015] Patent document: KR 10-2430199 Summary of the Invention

[0016] Overview

[0017] The purpose of this invention is to solve the above-mentioned problems and provide polymer compounds that prevent drug denaturation and enable stable and effective transdermal delivery.

[0018] Technical solution

[0019] To achieve the stated objective, the present invention provides a method for preparing a compound represented by Formula 1, the method comprising the steps of preparing a mixture by adding a catalyst and an initiator represented by M-OR; and the step of ring-opening polymerization of a monomer represented by Formula 2 in the mixture.

[0020] Formula 1

[0021] Formula 2

[0022] in: R 1 R 2 R 3 and R 4 Each is independently selected from: hydrogen, hydroxyl group, azide, acetyl group, C1-C 20 Alkyl groups, C2-C 20 alkenyl groups, C1-C 20 alkoxy group, C6-C 20 aryl group, C2-C 20 Heterocyclic groups and C3-C 20 Aliphatic groups; n is an integer from 10 to 600; R represents hydrogen, C1-C 20 Alkyl groups or -Si-(C1-C) 10 alkyl groups); M is hydrogen, an alkali metal, or an alkaline earth metal.

[0023] The catalyst may be one or more selected from citric acid, trifluoroacetic acid, phosphoric acid, acetic acid, sodium hydroxide, hydrochloric acid, and malonic acid.

[0024] The initiator may be one or more selected from trimethylsilyl alkoxide, tert-butoxide, methanol, ethanol, isopropoxide, methanol, ethanol, propanol, isopropanol, tert-butanol, butanol, pentanol, and hexane.

[0025] On the other hand, the present invention provides compounds represented by Formula 1: Formula 1

[0026] in: R 1 R 2 R 3 and R 4 Each is independently selected from: hydrogen, hydroxyl group, azide, acetyl group, C1-C 20 Alkyl groups, C2-C 20 alkenyl groups, C1-C 20 alkoxy group, C6-C 20 aryl group, C2-C 20 Heterocyclic groups and C3-C 20 Aliphatic groups; n is an integer from 10 to 600; R is C1-C 20 Alkyl groups or -Si-(C1-C) 10 alkyl groups).

[0027] Preferably, R is methyl, ethyl, isopropyl, tert-butyl, or -Si-(CH3)3.

[0028] Preferably, the molecular weight of the compound is from 1,000 g / mol to 100,000 g / mol.

[0029] On the other hand, the present invention provides a composition containing a compound represented by Formula 1 for transdermal delivery of an active substance.

[0030] Transdermal delivery involves delivery to the epidermis, dermis, and subcutaneous tissue.

[0031] Compositions for transdermal delivery may also contain an active substance. The active substance may be one or more selected from pharmaceuticals, cosmetics, diagnostic reagents, and imaging agents, and may be loaded into a compound represented by Formula 1.

[0032] In another aspect, the present invention provides a method for transdermal delivery of an active substance to an animal other than a human, the method comprising the step of administering a composition for transdermal delivery.

[0033] The effects of the invention

[0034] The polymer compound according to the invention exhibits high biocompatibility and provides high absorption and permeability when drugs are encapsulated within it. Therefore, it can be used as a novel drug carrier for transdermal absorption.

[0035] Furthermore, since the compound exhibits excellent therapeutic effects when drugs related to Alzheimer's disease, tumors, and hair loss are encapsulated in it, the compound can be used as an agent for treating Alzheimer's disease, tumors, and hair loss. Attached Figure Description

[0036] Figure 1a and Figure 1b It shows the use of each 1 H NMR (CDCl3) and 13 A graph showing the structural analysis of the polymer compound PDDS-ethyl according to an embodiment of the present invention using C NMR (CDCl3).

[0037] Figure 2a and Figure 2b It shows the use of each 1 H NMR (CDCl3) and 13 A graph showing the structural analysis of the polymer compound PDDS-isopropyl according to an embodiment of the present invention using C NMR (CDCl3).

[0038] Figure 3 It shows the use of 1 A graph showing the structural analysis of the polymer compound PDDS-tert-butyl according to an embodiment of the present invention using ¹H NMR (CDCl₃).

[0039] Figure 4 It is displayed according to the use 1 A graph showing the structural analysis of the polymer compound PDDS-methyl according to an embodiment of the present invention using ¹H NMR (CDCl₃).

[0040] Figure 5 It shows the use of 1 A graph showing the structural analysis of the polymer compound PDDS-TMS according to an embodiment of the present invention using ¹H NMR (CDCl₃).

[0041] Figure 6 The results of a short-term in vivo toxicity analysis of the polymer compound PDDS-ethyl according to an embodiment of the present invention are shown.

[0042] Figure 7 The results of efficacy analyses obtained by oral and transdermal administration of donepezil loaded into polymer compounds according to embodiments of the present invention to mouse models of Alzheimer's disease are shown.

[0043] Figure 8a and Figure 8b The results show the analysis of anticancer efficacy obtained by loading 5-aminolevulinic acid (5-ALA) into a PDDS-methyl polymer compound according to an embodiment of the present invention and delivering it percutaneously to a mouse model of cancer (thigh).

[0044] Figure 9 The results show the analytical effects on hair growth after minoxidil was loaded into a polymer compound according to an embodiment of the invention. Detailed Implementation

[0045] The invention will be described in further detail below. However, the invention may be embodied in various different forms and is not limited to the examples described herein, but is defined only by the claims listed below.

[0046] Furthermore, the terminology used herein is for describing particular embodiments only and is not intended to limit the invention. Throughout the specification, the term "comprising" means that another element may be further included, rather than excluded, unless otherwise expressly stated. The term "comprising" also includes the element used alone.

[0047] One aspect of the present invention provides novel polymer compounds.

[0048] To address the drawbacks of conventional polymers used in transdermal drug delivery systems (TDDS) while incorporating their advantages, the inventors have developed a series of polydimethylsilylethylene dimethylsiloxane (PDDS) compounds through ring-opening polymerization of monomers having cyclic siloxane structures. These PDDS compounds are silicone polymer compounds having a structure similar to that of polydimethylsiloxane (PDMS).

[0049] The PDDS series of this invention has a structure similar to PDMS, thus exhibiting the high biocompatibility, hydrophobicity, and high viscosity of PDMS. Furthermore, the abundant hydroxyl groups (-OH) in chitosan and hyaluronic acid are introduced at the ends, thereby endowing both hydrophilicity and hydrophobicity.

[0050] The mechanical and chemical properties of the PDDS series of the present invention can be controlled differently depending on factors such as the type of catalyst, the ratio of monomer to initiator, and the polymerization temperature.

[0051] The polymer compounds according to the present invention, namely the above-described PDDS series, can be represented by Formula 1.

[0052] Formula 1

[0053] in: R 1 R 2 R 3 and R 4 Each is independently selected from: hydrogen, hydroxyl group, azide, acetyl group, C1-C 20 Alkyl groups, C2-C 20 alkenyl groups, C1-C 20 alkoxy group, C6-C 20 aryl group, C2-C 20 Heterocyclic groups and C3-C 20 Aliphatic groups; n is an integer from 10 to 600; R is C1-C 20 Alkyl groups or -Si-(C1-C) 10 alkyl groups).

[0054] Preferably, R is methyl, ethyl, isopropyl, tert-butyl, or -Si-(CH3)3.

[0055] The compounds can have molecular weights ranging from 1,000 g / mol to 100,000 g / mol, but are not limited to this.

[0056] On the other hand, the present invention provides a method for preparing a compound represented by Formula 1, the method comprising the steps of preparing a mixture by adding a catalyst and an initiator represented by M-OR; and the step of carrying out ring-opening polymerization of a monomer represented by Formula 2 in the mixture.

[0057] Formula 1

[0058] Formula 2

[0059] in: R 1 R 2 R 3 and R 4 Each is independently selected from: hydrogen, hydroxyl group, azide, acetyl group, C1-C 20 Alkyl groups, C2-C 20 alkenyl groups, C1-C 20 alkoxy group, C6-C 20 aryl group, C2-C 20 Heterocyclic groups and C3-C 20 Aliphatic groups; n is an integer from 10 to 600; R represents hydrogen, C1-C 20 Alkyl groups or -Si-(C1-C) 10 alkyl groups); M is hydrogen, an alkali metal, or an alkaline earth metal.

[0060] In one embodiment, the catalyst may be one or more selected from citric acid, trifluoroacetic acid, phosphoric acid, acetic acid, sodium hydroxide, hydrochloric acid, and malonic acid, but is not limited thereto.

[0061] The initiator may be one or more selected from, but not limited to, alkoxides, trimethylsilyl alkoxides, tert-butoxides, methoxides, ethanols, isopropoxides, methanol, ethanol, propanol, isopropanol, tert-butanol, butanol, pentanol, and hexane.

[0062] R can vary depending on the type of initiator, and the physical properties of the prepared compound can be controlled by adjusting the type of one or more catalysts, the molar ratio of initiator to monomer, and the polymerization temperature.

[0063] On the other hand, the present invention provides a composition comprising a compound represented by Formula 1 for transdermal delivery of an active substance.

[0064] The composition for transdermal delivery may further comprise an active substance, preferably loaded into a compound represented by Formula 1.

[0065] The term “loaded” is used interchangeably with terms such as “support” and “encapsulation”, and can refer to, but is not limited to, a mixture of polymer compounds and active substances that are physically or chemically combined.

[0066] In one embodiment, the active substance may be a transdermal application agent or formulation, and the composition for transdermal delivery may increase the transdermal absorption of the active substance.

[0067] In one embodiment, the composition for transdermal delivery may further comprise an active substance requiring transdermal delivery, such as a transdermal formulation requiring increased transdermal absorption. Transdermal absorption can occur in the epidermis, dermis, and subcutaneous tissue.

[0068] Active substances can be loaded into the polymer compounds of the present invention to increase their transdermal absorption rate. Specifically, active substances can be loaded into the chain structure of the polymer compounds to increase their transdermal absorption rate.

[0069] The active substance may be one or more selected from pharmaceuticals, cosmetics, diagnostic reagents and imaging agents, but is not limited to these.

[0070] In one embodiment, the drug may be in one or more dosage forms selected from, but not limited to, ointments, creams, gels, emulsions, sprays, patches, aerosols, emulsions, and suspensions.

[0071] Cosmetics can be in one or more forms selected from skin toners, lotions, creams, serums, solutions, topical ointments, foams, colognes, nourishing lotions, moisturizing lotions, dressings, emollients, emulsions, sunscreens, sun oils, suspensions, emulsions, creams, gels, powders, essences, emulsions, serums, foundations, and sheet masks, but are not limited thereto.

[0072] In another aspect, the present invention provides a method for transdermal delivery of an active substance to an animal other than a human, the method comprising the step of administering a composition for transdermal delivery.

[0073] In one embodiment, a method for transdermal delivery of an active substance includes applying the active substance to a subject requiring treatment. The subject requiring treatment may refer to a patient, and the subject can be any mammal, including not only humans and primates, but also livestock such as cattle, pigs, sheep, horses, dogs, and cats.

[0074] In the following description, the invention will be illustrated in more detail by way of examples. These examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.

[0075] The compounds represented by Formula 1 according to the present invention can be synthesized by the synthetic routes shown in reaction schemes 1 to 3, but are not limited thereto.

[0076] In reaction schemes 1 to 3, the ROH can be selected from fatty alcohols (substituted or unsubstituted C1-C). 10 Alkyl groups), allyl alcohols, aromatic alcohols (substituted or unsubstituted C3-C8 aryl or heteroaryl groups), phenols, cresols, hydroquinones, catechols, resorcinols, phloroglucinols, and benzyl alcohols, but not limited to these.

[0077] Example 1: Synthesis of Polymer Compounds

[0078] 1) ROH + catalyst

[0079] <Reaction Scheme 1>

[0080] Specifically, ROH and catalyst were added to the reactor and dissolved at 20°C to 40°C. 5 g of the monomer 2,2,5,5-tetramethyl-1,2,5-oxadisilcyclopentane (TDOP) was added, and the mixture was refluxed for 24 to 48 hours. The reaction solution was cooled to room temperature, and the reaction was terminated by adding purified water. n-Heptane was added to extract the polymer, and the organic layer was washed with purified water. The separated organic layer was then concentrated under vacuum to obtain the final compound.

[0081] The reaction conditions for reaction scheme 1 are shown in Table 1.

[0082] [Table 1]

[0083] 2) Cyclohexane + ROH + catalyst

[0084] <Reaction Scheme 2>

[0085] The reaction conditions for reaction scheme 2 are shown in Table 2.

[0086] [Table 2]

[0087] 3) M-OR + catalyst

[0088] <Reaction Scheme 3>

[0089] In reaction scheme 3, M can be Li, Na, or K, but is not limited to these.

[0090] The reaction conditions for reaction scheme 3 are shown in Table 3.

[0091] [Table 3]

[0092] Experimental Example 1: In vivo toxicity analysis

[0093] PDDS-ethyl polymer was administered daily to the entire back of Balb / c-nu / nu mice at doses of 100 μL, 200 μL, and 400 μL for 7 days. Skin rash, total organ changes, organ weight changes, and body weight changes were then evaluated. As results ( Figure 6 No changes in organ weight or body mass were observed, and organ morphology was maintained. No in vivo toxicity of the PDDS-Et polymer was observed at doses up to 400 μL.

[0094] Experimental Example 2: The Role of Compounds Loaded with Donepezil

[0095] Donepezil is a representative Alzheimer's disease medication, widely used clinically to alleviate symptoms. It is currently administered orally, but due to various side effects, a transdermal formulation is needed.

[0096] In this invention, the efficacy of donepezil-loaded polymers against Alzheimer's disease was evaluated in a mouse model of Alzheimer's disease via oral administration and transdermal delivery.

[0097] In a mouse model of Alzheimer's disease induced by scopolamine, oral or transdermal administration of the drug was performed for 7 days, while simultaneously conducting Y-maze and passive avoidance test (PAT) behavioral experiments. The Y-maze was performed on day 4, and the PAT was performed on days 5 and 6. Mice were sacrificed on day 7, and acetylcholine (AChE) levels were measured. For AChE level determination: the mouse brain was removed and homogenized, acetylcholinesterase was extracted from the brain, and its level was measured using a kit.

[0098] In a Y-shaped maze, mice were placed in the maze, with each arm designated as a, b, and c, and the paths the mice took through the arms were recorded for 8 minutes. The spontaneous alternation rate was calculated as follows.

[0099] Spontaneous alternation rate = {Number of times abc, bca, cab, acb, bac, or cba appear in a continuous path / (Total number of arm entries - 2)} × 100

[0100] The Passive Avoidance Test (PAT) was conducted over two days, divided into an acquisition phase on day 1, during which mice acquired the traumatic memory, and a retention phase on day 2, during which the mice's retention of the acquired memory was evaluated. On day 1, mice were initially placed in a brightly lit compartment with the passageway connecting to a dark compartment open. When the mice entered the dark compartment, the passageway was closed, and an electric shock was applied to induce the traumatic memory. On day 2, mice were placed in the brightly lit compartment with the passageway leading to the dark compartment open. The retention of the memory was assessed based on the time spent in the brightly lit compartment.

[0101] As a result ( Figure 7 The memory impairment caused by scopolamine was significantly improved by the donepezil-loaded polymer. Improved memory and increased acetylcholine levels were confirmed in a mouse model of Alzheimer's disease.

[0102] Experimental Example 3: The Role of Compounds Loaded with 5-ALA

[0103] 5-Aminolevulinic acid (5-ALA) is a type of photodynamic therapy agent based on light irradiation, and it is a prodrug that undergoes structural changes to become a photoresponsive substance after being administered to the human body.

[0104] After loading 5-ALA into PDDS-methyl polymer, it was transdermally administered to the thighs of a mouse model of melanoma at doses of 100 μL / day and 200 μL / day, respectively, for 7 days, followed by 10 days of light exposure, to evaluate the cancer-specific therapeutic efficacy. Changes in mouse body weight, tumor size, and fluorescence after transdermal penetration were also assessed.

[0105] As a result ( Figure 8a and Figure 8b Observations of tumors isolated from mice confirmed that 5-ALA, upon local application, is absorbed by the dermis, undergoes a photoresponsive structural change, and is biosynthesized in mice as protoporphyrin IX (PpIX), which exhibits fluorescence. Furthermore, compared to the control group, cancer cell volume was reduced by at least 75% after treatment with 5-ALA and phototherapy.

[0106] These results suggest that the novel formulation can serve as a new approach for transdermal photodynamic therapy.

[0107] Experimental Example 4: The Role of Compounds Loaded with Minoxidil

[0108] Minoxidil is a representative low molecular weight organic compound that promotes hair growth and is used in a variety of hair loss-related products.

[0109] When C57BL mice were treated with PDDS-ethyl polymer loaded with minoxidil for 9 days, hair growth rate increased significantly from 2.5%. Figure 9 Therefore, the side effects caused by the high drug content of traditional products are expected to decrease.

[0110] In summary, the novel polymer compounds according to the present invention exhibit excellent biocompatibility, provide good encapsulation efficiency when loaded with active substances, and increase absorption through transdermal delivery. Therefore, they can be used as transdermal delivery agents in transdermal delivery systems.

[0111] Therefore, it should be understood that the above embodiments are illustrative in all respects and are not intended to limit the invention. The scope of the invention is defined by the following claims, not by the foregoing detailed description, and all variations or modifications derived from the meaning and scope of the claims and their equivalents should be interpreted as falling within the scope of the invention.

[0112] Industrial applicability

[0113] The novel polymer compounds provided by this invention can be applied to pharmaceuticals, health functional foods, medical devices, etc.

Claims

1. A method for preparing a compound represented by Formula 1, comprising the steps of preparing a mixture by adding a catalyst and an initiator represented by M-OR; and the step of causing a monomer represented by Formula 2 to undergo ring-opening polymerization in the mixture: Formula 1 Formula 2 in: R 1 R 2 R 3 and R 4 Each is independently selected from: hydrogen, hydroxyl group, azide, acetyl group, C1-C 20 Alkyl groups, C2-C 20 alkenyl groups, C1-C 20 alkoxy group, C6-C 20 aryl group, C2-C 20 Heterocyclic groups and C3-C 20 Aliphatic groups; n is an integer from 10 to 600; R represents hydrogen, C1-C 20 alkyl groups or -Si-(C1-C) 10 alkyl groups); M is hydrogen, an alkali metal, or an alkaline earth metal.

2. The method according to claim 1, wherein the catalyst is selected from one or more of citric acid, trifluoroacetic acid, phosphoric acid, acetic acid, sodium hydroxide, hydrochloric acid, and malonic acid.

3. The method according to claim 1, wherein the initiator is one or more selected from trimethylsilyl alkoxide, tert-butoxide, methanol, ethanol, isopropoxide, methanol, ethanol, propanol, isopropanol, tert-butanol, butanol, pentanol, and hexane.

4. Compounds represented by Formula 1: Formula 1 in: R 1 R 2 R 3 and R 4 Each is independently selected from: hydrogen, hydroxyl group, azide, acetyl group, C1-C 20 Alkyl groups, C2-C 20 alkenyl groups, C1-C 20 alkoxy group, C6-C 20 aryl group, C2-C 20 Heterocyclic groups and C3-C 20 Aliphatic groups; n is an integer from 10 to 600; R is C1-C 20 alkyl groups or -Si-(C1-C) 10 alkyl groups).

5. The compound according to claim 4, wherein R is methyl, ethyl, isopropyl, tert-butyl or -Si-(CH3)3.

6. The compound according to claim 4, wherein the molecular weight of the compound is from 1000 g / mol to 100000 g / mol.

7. A composition for transdermal delivery of an active substance, comprising a compound represented by Formula 1 according to any one of claims 4 to 6.

8. The composition of claim 7, wherein the transdermal delivery is delivered to the epidermis, dermis, and subcutaneous tissue.

9. The composition according to claim 7, further comprising an active substance.

10. The composition according to claim 9, wherein the active substance is selected from one or more pharmaceuticals, cosmetics, diagnostic reagents, and imaging agents.

11. The composition according to claim 9, wherein the active substance is loaded into the compound represented by formula 1.

12. A method for transdermal delivery of an active substance, comprising applying the composition for transdermal delivery according to claim 7.

Citation Information

Patent Citations

  • Hyaluronic acid-polymer nanoparticles capable of transdermal delivery and application thereof

    KR102430199B1